3Chowdhurg NR, Arias IM, Wolkoff AW, et al. Disorders of bilirubin metabolism. In: Arias IM, Boyer JL, Chiasari FV, et al, eds. The liver:biology and pathobioloby. 4th ed. Philadelphia: USA. Lippincot Williams and Wilkins, 2001. 291-310.
4Chrawford JM. Bilirubin metabolism and the pathophysiology of jaundice. In: Schiff ER, Sorrell MF, Maddrey WC eds. Schiff's diseases of the liver . 9th ed. Philadelphia: USA. Lippincott Williams and Wilkins, 2003. 167-220.
5Owens IS, Ritter JK, Yeatman MT, et al. The noval UGT1 gene complex links bilirubin, xenobiotics, and therapeutic drug metabolism by encoding UOP glucuronosyltransferase isozymes with a common carboxyl terminus. J Pharmacokin Biopharm, 1996,24: 491-508.
6Tiribelli C, Ostrow JD. New concepts in bilirubin and jaundice. Hepatology, 1996,24: 1296-1308.
7Tukey PH, Strassburg CP. Human UDG-glucuronosytransferases:metabolism, expression and disease. Annu Rev Pharmacol Toxicol,2000,40: 581-616.
8Traunet M, Meier PJ, Boyer JL. Molecular regulation of hepatocellular transport system in cholestasis. J Hepatol, 1999, 31:165-178.
9Co vie A,Goldsmith DJ,Segall L,et al.Rifampicin-inducedacute renal failure:a series of 60 patients [J].Nephrol DialTransplant,1998,13(4):924-929.
10Pereira A,Sanz C,Cervantes F,et al.Immune hemolyticanemia and renal failure associated with rifampicin dependentantibodies with anti-I specificity [J].Ann Hematol,1991,63(1):56-58.
